The 540 basis point year-over-year expansion in gross margin is the most striking profitability signal, yet it coincides with flat revenue growth, implying the improvement is not driven by pricing power or mix shift but by one-time tariff cost recoveries. Operating margin of 21.3% in Q2 2026 versus 15.2% in the prior year quarter reflects the same distortion, as operating leverage amplified the gross margin swing. Investors should normalize for these recoveries to assess the underlying earning power, which appears to be in the low-to-mid teens operating margin range, consistent with the trailing four-quarter average.

The sequential improvement in ROIC from 2.2% in Q1 2026 to 4.5% in Q2 2026 is encouraging, but the absolute level remains modest for a company with a purported engineering moat. The gap versus peers like LKQ (7.2%) and ALSN (22.2%) suggests that Dorman's asset base, particularly its elevated inventory levels, is not generating commensurate returns. The company's asset turnover has been stagnant at 0.21-0.22 for ten quarters, indicating that margin expansion, not efficiency, is driving the ROIC recovery, which may be unsustainable if tariff recoveries fade.

The 48-day increase in DIO over the past year is a red flag, as it implies that inventory is growing faster than sales, which grew only 0.7% in Q2 2026. This may indicate that Dorman is building stock in anticipation of new SKU launches or that retail partners are destocking, leaving Dorman to absorb the inventory. The cash conversion cycle of 308 days is heavily influenced by the extended DIO, and while DPO has also risen, it has not kept pace, straining working capital. Investors should monitor whether this inventory build is a deliberate strategic bet or a sign of demand softening, as a future write-down could pressure earnings.

The reduction in leverage is notable, with D/E declining from 0.56 in Q1 2024 to 0.35 in Q2 2026, reflecting debt repayment and retained earnings growth. Interest coverage of 19.3x is robust, providing ample cushion against rate hikes, though the company's low debt-to-equity ratio (0.35) suggests it is not heavily reliant on debt financing. The improvement in D/EBITDA from 7.53 to 4.34 in one quarter is partly due to the spike in EBITDA from tariff recoveries, so the normalized leverage may be higher. Nonetheless, the balance sheet appears healthy, with no imminent refinancing risk given the low absolute debt levels.

The current ratio of 3.60 is well above the 2.0 threshold typically considered healthy, and the quick ratio of 1.73 suggests that even without selling inventory, Dorman can cover its short-term obligations. The increase in cash from $34.4M to $132M over the same period provides a solid buffer against working capital swings, which have been volatile. However, the high inventory levels that contribute to the current ratio also pose a risk, as a sudden write-down could erode the liquidity cushion. Overall, the liquidity position appears robust, but the quality of current assets is somewhat dependent on inventory valuation.